Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652150 | 0.94 | CRHR1 (0.38) | CRHR1TAS2R14C5AR1PTGESALOX5 | |
| SCHEMBL651093 | 0.94 | CRHR1 (0.37) | CRHR1MEP1BC5AR1MDM2TRPM8 | |
| SCHEMBL648626 | 0.94 | PIN1 (0.38) | CRHR1MDM2PIN1LPAR1LPAR5 | |
| SCHEMBL652145 | 0.93 | TLR7 (0.38) | CRHR1MEP1BC5AR1 | |
| SCHEMBL5220455 | 0.93 | AGTR1 (0.37) | CRHR1MEP1BC5AR1MDM2 | |
| SCHEMBL1913045 | 0.92 | SMN1; SMN2 (0.41) | CRHR1MEP1BTAS2R14C5AR1PTGES | |
| SCHEMBL647849 | 0.89 | CRHR1 (0.38) | CRHR1C5AR1MDM2 | |
| SCHEMBL650193 | 0.89 | CRHR1 (0.40) | CRHR1C5AR1 | |
| SCHEMBL1913047 | 0.88 | ALDH1A1 (0.36) | CRHR1C5AR1MDM2TRPM8 | |
| SCHEMBL651143 | 0.88 | CRHR1 (0.37) | CRHR1C5AR1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |